AOD-9604 is a synthetic 16-amino-acid fragment modeled on the fat-metabolism region of human growth hormone. The idea is elegant: keep the lipolysis signal, avoid the broad growth-hormone effects. The evidence is less glamorous. AOD-9604 reached human obesity trials, looked tolerable, and did not meaningfully raise IGF-1 or worsen glucose tolerance, but the later large Phase IIb obesity program did not support continued commercial development. It is not an FDA-approved obesity drug and is prohibited in sport.
AOD-9604 (Tyr-hGH177-191; YLRIVQCRSVEGSCGF; cyclic disulfide between Cys7 and Cys14) is a modified C-terminal hGH fragment developed from the lipolytic domain of hGH. The 2014 safety/metabolism review summarizes six human studies: two IV, two oral pilot studies, and two oral Phase IIb obesity studies, including approximately 300-subject and 536-subject programs. The dose architecture below intentionally separates evidence-grounded oral/IV exposure from speculative subcutaneous community practice, because controlled obesity studies were oral/IV, not SC.
AOD-9604 (CAS 221231-10-3; PubChem CID 71300630; DrugBank DB06388; C78H123N23O23S2; MW 1815.1 Da) is a disulfide-cyclized synthetic hGH fragment analog. PubChem and DrugBank identify it as a synthetic analog of the lipolytic domain of human growth hormone investigated for obesity. Mechanistic literature implicates reduced lipogenesis, increased lipolytic activity, beta-3 adrenergic pathway dependence in chronic obese-mouse models, and rapid degradation with short systemic half-life. Translation is the central problem: animal data are coherent; human weight-loss efficacy was mixed and ultimately commercially negative.
AOD-9604 is best read as a translational cautionary case: a clean concept, plausible preclinical fat-metabolism biology, and unusually real human exposure data for a peptide in this atlas, but no approved indication and no convincing modern obesity-drug efficacy. The engine must keep those two truths visible at the same time.
AOD-9604 was designed around the C-terminal region of hGH linked to lipolysis and anti-lipogenesis. The mechanism story is stronger in obese rodents than in human outcomes. This page therefore grades mechanism separately from clinical usefulness.
This is the main AOD-9604 engine layer: not a prescription, not medical advice, and not an approved obesity protocol. It separates study-grounded exposure from speculative SC use, then adds explicit titration, monitoring, and stop rules so the page cannot drift into vague "fat-loss peptide" marketing.
250 mcg SC once daily, usually modeled as a morning or fasted-state pulse. This is a practice-pattern anchor, not a clinical-trial dose.150 mcg -> 250 mcg -> 300 mcg -> 400 mcg -> 500 mcg/day. High speculative ceiling: 750 mcg/day only with explicit experimental flag and stronger monitoring.8-12 weeks, then stop and reassess. Washout 2-4 weeks. No indefinite "maintenance" default because efficacy is uncertain.| Band | Injectable community-model range | Approx mcg/kg/day at 90 kg | Basis |
|---|---|---|---|
| Low | 150-250 mcg/day | 1.7-2.8 | Conservative exposure; not validated |
| Standard | 250-500 mcg/day | 2.8-5.6 | Common SC practice range; speculative |
| High | 500-750 mcg/day | 5.6-8.3 | Escalated speculative range; avoid routine use |
| Historical oral | 1-30 mg/day | 11-333 at 90 kg | Human oral obesity trials used mg-level dosing |
| Body weight | Low ~2.5 mcg/kg | Standard ~5 mcg/kg | High ~7.5 mcg/kg |
|---|---|---|---|
| 55 kg | 140 mcg | 275 mcg | 410 mcg |
| 65 kg | 160 mcg | 325 mcg | 490 mcg |
| 75 kg | 190 mcg | 375 mcg | 560 mcg |
| 85 kg | 210 mcg | 425 mcg | 640 mcg |
| 95 kg | 240 mcg | 475 mcg | 710 mcg |
| 105 kg | 260 mcg | 525 mcg | 790 mcg |
UI rule: default to 250, 300, 400, and 500 mcg presets. Do not imply that 425 mcg is more evidence-based than 400 or 500 mcg.
| Trigger | Action | Rationale |
|---|---|---|
| No side effects after 14 days and no response trend | Consider step up by 50-100 mcg/day | Speculative escalation; avoid dose-chasing |
| Injection-site irritation | Hold or reduce; rotate site; verify source | Product quality and local tolerability first |
| Fasting glucose worsens meaningfully | Hold and evaluate metabolic status | Unexpected against reported trial neutrality |
| Edema, headache, fatigue, palpitations | De-escalate or hold | Non-specific but relevant to peptide/GH-axis caution |
| Active malignancy, pregnancy, breastfeeding | Hard stop | No adequate safety basis; growth-axis ambiguity |
| Competitive athlete | Hard stop | WADA-prohibited |
| No measurable outcome after 8-12 weeks | Stop/reassess | Weak efficacy evidence; avoid indefinite use |
| Marker | Why track | Validated for AOD-9604? |
|---|---|---|
| Body weight | Primary obesity-trial outcome | Outcome marker only |
| Waist circumference | Abdominal fat proxy | No |
| DEXA / InBody / skinfold trend | Fat vs lean-mass trend | No |
| Fasting glucose, insulin, HOMA-IR | Metabolic safety screen | No response validation |
| HbA1c | Longer-term glycemic trend | No |
| Lipid panel | Metabolic risk context | No |
| IGF-1 | GH-axis ambiguity check | Mechanistically relevant, not routine response marker |
| BP / HR | General metabolic-med safety | No |
| hs-CRP | Inflammation/metabolic context | No |
For research reference only. AOD-9604 is not FDA-approved and SC protocols are speculative. Verify identity, sterility, endotoxin limits, and source before any injectable research setting.
No controlled human study validates AOD-9604 stacks. Combination logic should keep AOD-9604 in a secondary, hypothesis-testing role and should never allow stronger therapies to make AOD look more effective than it is.
No controlled human study validates any AOD-9604 combination. Every stack above is a hypothesis layer, and the engine enforces one rule above all others: AOD-9604 stays in a secondary, hypothesis-testing role and is never credited with effects produced by stronger, better-evidenced agents. Where a partner agent (GLP-1/GIP, GHRH analog, lifestyle program) carries the real outcome, the protocol should make that explicit so that a weak fragment is not mistaken for the active driver. Combinations that re-introduce GH/IGF-1 elevation or stack adrenergic/thyroid load are discouraged because they trade away AOD's only defensible advantage — endocrine neutrality — for unproven gains.
Human studies summarized AOD-9604 as generally well tolerated, without meaningful IGF-1 stimulation, oral-glucose-tolerance worsening, or detected anti-AOD antibodies in selected tested participants. The central safety issue is not a dramatic known toxicity signal; it is unapproved use, uncertain product quality, unclear long-term outcomes, and efficacy overclaiming.
Given the unapproved status and limited human data, these are precautionary — based on mechanism, regulatory caution, and class effects, not on a documented AOD-9604 toxicity signal.
| Condition | Concern | Severity |
|---|---|---|
| Pregnancy | No adequate safety data | High |
| Breastfeeding | No adequate safety data | High |
| Active malignancy | Growth-axis ambiguity; no long-term cancer safety program | High |
| Competitive athlete | WADA-prohibited | High |
| Uncontrolled diabetes | Metabolic monitoring required; do not use as substitute for approved care | Moderate/High |
| Severe renal/hepatic disease | Unknown clearance/safety in special populations | Moderate |
| Active edema / heart failure risk | GH-axis class caution even if AOD is not full GH | Moderate |
| Peptide allergy history | Hypersensitivity risk | Moderate |
| Unverified injectable product | Sterility, endotoxin, identity, impurity risk | High |
| Children/adolescents | No clinical basis | High |
Weight, waist circumference, body-composition estimate (DEXA / InBody / skinfold), BP/HR, fasting glucose, insulin/HOMA-IR, HbA1c, lipid panel; pregnancy test if reproductive potential; malignancy history review; IGF-1 if GH-axis ambiguity is being tracked. Document product purity / sterility / endotoxin before any injectable use.
Tolerability and injection-site review; confirm no new glycemic, edema, or hypersensitivity flag. No response judgment yet — too early. Escalation gate opens only if tolerated and a measured trend is being tracked, not chased.
Repeat waist + body-composition estimate and weight trend against diet/exercise baseline; targeted safety labs if any symptom flag (fasting glucose, CMP). Decision: continue, hold, or step per titration logic.
Objective-outcome checkpoint: waist down, body-fat estimate down, or scale trend beyond diet/exercise noise. If no measurable outcome, stop rather than escalate indefinitely — the weak efficacy evidence does not justify dose-chasing.
Confirm trajectory off-drug and re-screen metabolic markers. Decide whether any further cycle is justified by clear prior, measurable benefit — not by hope or sunk cost.
Pregnancy/lactation, new or progressing malignancy, unexplained IGF-1 elevation, meaningful fasting-glucose worsening, significant injection-site or systemic allergic reaction, competitive-sport exposure (WADA), or inability to verify product identity/sterility.
AOD-9604 is unusual among research peptides because it has real human development history. That history is exactly why the page must be restrained: safety/tolerability was not the problem; robust weight-loss efficacy was.
| Study/program | Design | Route / dose | Outcome | Grade |
|---|---|---|---|---|
| Human IV pilots | Safety / PK pilots | IV; dose details summarized but not all public | Tolerability data reported | B/C exposure |
| Oral pilot studies | Safety / PK pilots | Oral | Tolerability data reported | B/C exposure |
| 12-week oral obesity dose-finding | Randomized controlled study, about 300 adults | 1, 5, 10, 20, 30 mg/day oral arms | Modest weight-loss signal, strongest at lower dose; not clean dose-response | B |
| Phase IIb OPTIONS / METAOD006 | Randomized double-blind obesity trial, 536 adults, 24 weeks | Lower-dose oral program | Did not support continued development for obesity | B |
| Obese rodent models | Preclinical | SC minipump / oral / IP depending model | Reduced fat gain, increased oxidation/lipolysis in obese models | P/C |
| Beta-3 AR knockout work | Preclinical mechanism | Obese mice / knockout models | Chronic effect linked to beta-3 adrenergic signaling | P/C |
| Toxicology / PK program | Rat, pig, monkey, human summaries | Oral and IV focus | Rapid degradation; high-dose animal tolerability; no major glucose/IGF-1 issue in humans | C/B safety |
The key human-data anchor: summarizes six human clinical studies (two IV, two oral pilots, two oral Phase IIb obesity programs), reporting no meaningful IGF-1 rise, no oral-glucose-tolerance worsening, antibody findings, and rapid PK/degradation, alongside animal toxicology. Frames AOD-9604 as a tolerable but unproven-for-efficacy metabolic agent.
FDA briefing materials note the 536-subject obesity trial did not demonstrate the weight-loss effect needed to support the obesity indication; commercial obesity development did not continue. The accompanying clinical summary describes the ~300-subject oral study and the 536-subject Phase IIb design with diet/exercise conditions. This is the decisive negative-efficacy evidence.
Chronic treatment with hGH or a modified C-terminal fragment increased fat oxidation and reduced body weight/fat in an obese-mouse model — the foundational preclinical evidence for the lipolytic/anti-lipogenic concept and the strongest part of the mechanism story.
Beta-3-adrenoceptor knockout / obese-mouse work implicated beta-3 adrenergic receptor signaling as necessary for the chronic anti-obesity effect of hGH / AOD9604. Establishes the adrenergic node as causal in rodents, with unknown human translation. Earlier lipolytic-domain work localized the fat-metabolism activity to the C-terminal hGH sequence.
The December 4, 2024 Pharmacy Compounding Advisory Committee reviewed AOD-9604 free base and acetate as bulk drug substances for obesity under 503A bulks-list consideration. 503A bulks-list status is a compounding-policy determination distinct from FDA drug approval — not a finding of efficacy.
PubChem records AOD-9604 as C78H123N23O23S2, CAS 221231-10-3, CID 71300630 — a synthetic analogue of the lipolytic domain of hGH investigated for obesity; DrugBank (DB06388) lists it as an investigational anti-obesity peptide. WADA prohibits growth-hormone fragments including AOD-9604 — a hard stop for tested athletes.
AOD-9604 occupies an unusual position in this atlas: its tolerability/safety evidence is comparatively real (human IV and oral studies, no major IGF-1 or glucose signal), while its efficacy evidence for obesity is negative at the decisive step — the 536-subject Phase IIb did not support development. The preclinical mechanism (lipolysis, beta-3 dependence, anti-lipogenesis) is coherent but concentrated in obese-rodent models, and human translation was weak. Overall obesity-efficacy grade is LOW and commercially negative; subcutaneous, intranasal, topical, and "spot-fat" protocols remain grade D/P. This is precisely why the dosing engine above is framed as a research/protocol-modeling layer with mandatory stop/reassess logic, not a guideline.
The honest comparison is unflattering: AOD-9604's neighbors include approved, outcome-validated obesity drugs. Placing it beside them keeps expectations calibrated — AOD is a tolerable, non-somatogenic fragment with a failed efficacy program, not a peer of GLP-1-class therapy.
| Parameter | AOD-9604 | Semaglutide (GLP-1) | Tirzepatide (GIP/GLP-1) | Tesamorelin (GHRH) |
|---|---|---|---|---|
| Structure | 16-AA cyclic hGH C-terminal fragment analog | GLP-1 receptor agonist (acylated peptide) | Dual GIP/GLP-1 receptor agonist | Synthetic GHRH(1-44) analog |
| Primary mechanism | Adipose lipolysis / anti-lipogenesis; beta-3 dependence (preclinical) | Appetite suppression, delayed gastric emptying, central satiety | Dual incretin appetite/metabolic control | Stimulates endogenous GH → visceral-fat reduction |
| Approval status | Not FDA-approved for any indication | FDA-approved (obesity, T2D) | FDA-approved (obesity, T2D) | FDA-approved (HIV-associated lipodystrophy) |
| Human efficacy | Phase IIb obesity trial negative; development discontinued | Large RCTs: substantial, durable weight loss | Largest weight-loss effect sizes in class | Reduces visceral adipose tissue in its indication |
| Growth-axis effect | No meaningful IGF-1 rise (its main selling point) | None | None | Raises GH/IGF-1 (intended) |
| Route | Oral/IV in trials; SC community use unvalidated | SC weekly (oral form exists) | SC weekly | SC daily |
| WADA status | Prohibited (GH fragment / S0) | Not prohibited | Not prohibited | Prohibited (S2, GH-axis) |
| Best framing | Tolerable but efficacy-negative research fragment | First-line evidence-based obesity therapy | Highest-efficacy obesity therapy | Niche GH-axis visceral-fat agent |